Morgan Stanley Viracta Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 30,669 shares of VIRX stock, worth $4,907. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,669

Previous 134,544 77.21%

Holding current value

$4,907

Previous $72,000 90.28%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.21 - $0.56 $21,813 - $58,170	-103,875 Reduced 77.21%	30,669 $7,000
Q2 2024 Oct 17, 2024	BUY	$0.5 - $1.17 $8,264 - $19,337	16,528 Added 14.0%	134,544 $72,000
Q2 2024 Aug 14, 2024	BUY	$0.5 - $1.17 $8,264 - $19,337	16,528 Added 14.0%	134,544 $72,000
Q1 2024 Oct 17, 2024	SELL	$0.48 - $1.13 $7,933 - $18,676	-16,528 Reduced 12.28%	118,016 $120,000
Q1 2024 Aug 16, 2024	BUY	$0.48 - $1.13 $14,724 - $34,662	30,675 Added 35.12%	118,016 $120,000
Q1 2024 May 15, 2024	BUY	$0.48 - $1.13 $14,724 - $34,662	30,675 Added 35.12%	118,016 $120,000
Q4 2023 Aug 16, 2024	SELL	$0.44 - $1.04 $20,769 - $49,091	-47,203 Reduced 35.08%	87,341 $49,000
Q4 2023 Feb 13, 2024	BUY	$0.44 - $1.04 $11,930 - $28,199	27,115 Added 45.02%	87,341 $49,000
Q3 2023 Nov 15, 2023	BUY	$1.03 - $1.58 $1,417 - $2,174	1,376 Added 2.34%	60,226 $62,000
Q2 2023 Aug 14, 2023	BUY	$0.89 - $2.13 $2,637 - $6,313	2,964 Added 5.3%	58,850 $82,000
Q1 2023 May 15, 2023	SELL	$1.38 - $2.29 $8,411 - $13,957	-6,095 Reduced 9.83%	55,886 $88,000
Q4 2022 Feb 14, 2023	SELL	$1.26 - $4.38 $5,305 - $18,444	-4,211 Reduced 6.36%	61,981 $90,000
Q3 2022 Nov 14, 2022	SELL	$3.32 - $5.69 $73,385 - $125,771	-22,104 Reduced 25.03%	66,192 $282,000
Q2 2022 Oct 27, 2022	BUY	$1.87 - $5.0 $38,510 - $102,970	20,594 Added 30.42%	88,296 $343,000
Q2 2022 Aug 15, 2022	BUY	$1.87 - $5.0 $38,510 - $102,970	20,594 Added 30.42%	88,296 $343,000
Q1 2022 Oct 27, 2022	SELL	$2.23 - $4.76 $45,924 - $98,027	-20,594 Reduced 23.32%	67,702 $322,000
Q1 2022 May 13, 2022	SELL	$2.23 - $4.76 $1.13 Million - $2.42 Million	-508,375 Reduced 88.25%	67,702 $322,000
Q4 2021 Feb 14, 2022	BUY	$3.37 - $7.91 $1.84 Million - $4.31 Million	544,576 Added 1728.76%	576,077 $2.1 Million
Q3 2021 Nov 15, 2021	BUY	$7.84 - $12.53 $246,967 - $394,707	31,501 New	31,501 $253,000

Others Institutions Holding VIRX

# of Institutions

Shares Held

5.63M

Call Options Held

Put Options Held

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $6.01M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account